Skip to main content
. 2008 Sep;3(5):1511–1525. doi: 10.2215/CJN.04140907

Figure 1.

Figure 1.

Effects of RAS inhibitor therapy compared with placebo according to the DD, ID, or II genotype. A meta-analysis of two prospective, randomized, double-blind, placebo-controlled trials in patients with diabetic or nondiabetic proteinuric nephropathies.